1.0Sickle Cell Disease Association of America Inc.https://www.sicklecelldisease.orgEmma Dayhttps://www.sicklecelldisease.org/author/emma/MARAC Statement: Crizanlizumab (Adakveo) - Sickle Cell Disease Association of America Inc.rich600338<blockquote class="wp-embedded-content" data-secret="3iC2j1LVbB"><a href="https://www.sicklecelldisease.org/2023/07/07/marac-statement-crizanlizumab-adakveo/">MARAC Statement: Crizanlizumab (Adakveo)</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.sicklecelldisease.org/2023/07/07/marac-statement-crizanlizumab-adakveo/embed/#?secret=3iC2j1LVbB" width="600" height="338" title="“MARAC Statement: Crizanlizumab (Adakveo)” — Sickle Cell Disease Association of America Inc." data-secret="3iC2j1LVbB" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
July 7, 2023 – SCDAA’s Medical and Research Advisory Committee (MARAC) notes that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended on May 26, 2023, that the conditional marketing authorization for crizanlizumab (Adakveo) be revoked. The EMA stated that this revocation was triggered by the findings of the Novartis […]https://www.sicklecelldisease.org/wp-content/uploads/2020/12/H-1404-MARAC-Alert-new-header-for-Constant-Contact_300ppi3.jpg